

1 ATGAGCTTATATGGAGAAAGTGGTAAAGTAAAGTCTGTGTGACGACAC 50
 17 TAAATProteinThruAlaValLeuAlaValSerGlnSerLeuLeuSerHisHis 34
 18 GGG 100
 51 GGG 100
 64 GGG 50
 101 GGG 150
 51 GGG 67
 151 GGG 200
 67 GGG 84
 201 GGG 250
 84 GGG 100
 251 GGG 300
 111 GGG 117
 351 GGG 350
 117 GGG 134
 401 GGG 400
 134 GGG 150
 451 GGG 450
 151 GGG 167
 501 GGG 500
 167 GGG 184
 551 GGG 550
 184 GGG 200
 601 GGG 600
 201 GGG 217
 651 GGG 650
 217 GGG 234
 701 GGG 700
 234 GGG 250
 751 GGG 750
 251 GGG 267
 801 GGG 800
 267 GGG 284
 851 GGG 850
 284 GGG 300
 901 GGG 900
 301 GGG 317
 951 GGG 950

317 TARGSerTyrPheSerGlnPheAlaLysLeuAsnHisSerHisSerHisVal 334
 951 GGG 1000
 334 SPValHisGlyPheGlyHisLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 350
 1001 GGG 1050
 351 ProAspSerValProValAspSerPheProValPheSerMetAlaVal 367
 1051 GGG 1100
 367 ValAlaValLeuGlnSerThrLeuSerGlySerHisValYserAsnGly 384
 1101 GGG 1150
 384 GProThrHisSerArgLeuGlnGlnMetProLeuPheSerAspValLeu 400
 1151 GGG 1200
 401 LeuThrThrSerGlnLysProGlnPheGlnHisLeuThrThrLysLeuGly 417
 1201 GGG 1250
 417 ValAlaValLeuGlnSerThrLeuSerGlySerHisValYserAsnGly 434
 1251 GGG 1300
 434 ValLysGlnHisLeuGlnSerThrLeuSerGlySerHisValYserAsn 450
 1301 GGG 1350
 451 GlySerGlnGlnSerThrLeuSerGlySerHisValYserAsnGly 467
 1351 GGG 1400
 467 TysArgSerAlaLeuGlnAsnSerGlnLysHisSerAlaAlaValSerVal 484
 1401 GGG 1450
 484 AsnSerAsnSer...GlySerGlnLysSerSerProValHisSerPro 499
 1451 GGG 1500
 499 SerSerProThrProProSerThrSerGlyValSerAlaLeuProGly 516
 1501 GGG 1550
 516 GProThrProProProProProAlaAlaAlaAlaAlaAlaAlaAlaAla 533
 1551 GGG 1600
 533 ValAlaProAlaLeuSerSerGlnAlaValAsnGlyMetSerArgGly 549
 1601 GGG 1650
 550 AlaLeuLeuSerSerLeuGlnAsnPheGlnLysGlyThrLeuAlaValGly 566
 1651 GGG 1700
 566 GlyThrCysAspHisSerAlaProLysGlnGly 577
 1701 GGG 1750

seq_name: qf_pr:AK000342

seq_documentation_block: 2046 bp mRNA linear 11000
 LOCUS AK000342
 DEFINITION Homo sapiens CDNA FLJ20345, 1156, clone HRP1429.
 ACCESSION AK000342
 VERSION AK000342.1 GI:7020362
 KEYWORDS cDNA, capping, 5' (full), insert, sequence.

[illegible]

PR 17-NOV-2000: 2000US-0249209.
 PR 17-NOV-2000: 2000US-0249210.
 PR 17-NOV-2000: 2000US-0249211.
 PR 17-NOV-2000: 2000US-0249212.
 PR 17-NOV-2000: 2000US-0249214.
 PR 17-NOV-2000: 2000US-0249215.
 PR 17-NOV-2000: 2000US-0249216.
 PR 17-NOV-2000: 2000US-0249217.
 PR 17-NOV-2000: 2000US-0249218.
 PR 17-NOV-2000: 2000US-0249244.
 PR 17-NOV-2000: 2000US-0249245.
 PR 17-NOV-2000: 2000US-0249264.
 PR 17-NOV-2000: 2000US-0249265.
 PR 17-NOV-2000: 2000US-0249297.
 PR 17-NOV-2000: 2000US-0249299.
 PR 01-DEC-2000: 2000US-0250160.
 PR 01-DEC-2000: 2000US-0250161.
 PR 05-DEC-2000: 2000US-0250180.
 PR 05-DEC-2000: 2000US-0251988.
 PR 05-DEC-2000: 2000US-0256719.
 PR 06-DEC-2000: 2000US-0251479.
 PR 08-DEC-2000: 2000US-0251856.
 PR 08-DEC-2000: 2000US-0251864.
 PR 08-DEC-2000: 2000US-0251869.
 PR 08-DEC-2000: 2000US-0251989.
 PR 11-DEC-2000: 2000US-0254960.
 PR 11-DEC-2000: 2000US-0254967.
 PR 05-JAN-2001: 2001US-0256784.
 XX
 XX
 PR (H26A) H26A-0256784-0256784.
 XX
 PR Rosen CA, Barash SC, Rubin SM.
 VI
 PR WPI, 2001 46540250.
 PR P-PSDB: AN017470.
 DR
 XX
 PR Novel polypeptides useful for diagnosing, treating, preventing and/or
 PT prophesying disorders related to CCR proteins, including cancers, immune
 PT disorders and neuronal disorders
 PR
 PS
 XX
 PR Claim 1: SEQ ID NO 422: 880bp; EMBL:G1.

CC The invention relates to novel isolated polypeptides (I), and
 CC polynucleotides (II), (II) and (II) and the antibody to (I) are useful for
 CC diagnosing, preventing and treating diseases including immune system
 CC disorders (e.g., congenital and acquired immunodeficiencies, autoimmune
 CC disorders (e.g., rheumatoid arthritis), inflammatory conditions, organ
 CC transplant rejection and graft versus host disease, infectious diseases
 CC (e.g., hepatitis C), bleeding disorders, hemophilic abnormalities and
 CC other blood related disorders (e.g., sickle cell anemia), myeloproliferative
 CC disorders, primary hematopoietic disorders, myeloproliferative
 CC disorders (e.g., Gaucher's disease and others), neurodegenerative
 CC disorders (e.g., Alzheimer's disease, Parkinson's disease), chromosomal
 CC abnormalities (Down Syndrome), ischemic injury (e.g., stroke), renal
 CC disorders (e.g., glomerulonephritis), cardiovascular disorders
 CC (e.g., arthritis), respiratory disorders, neuroendocrine disorders, in
 CC wound healing, epithelial cell proliferation, and other disorders (e.g.,
 CC Addison's disease), reproductive system disorders, and other disorders.
 CC disorders (inflammatory disorders). These disorders (e.g., diabetes),
 CC as stimulators of B-cell responses, as T cell activators, and as means to induce
 CC tumor proliferation in pathologies (e.g., acquired immune deficiency
 CC syndrome (AIDS), MS27950, MS27950, MS27950, MS27950, MS27950, MS27950,
 CC pathway protein coding sequences and PCR primers of the invention.
 XX

alignment_scores:

quality: 640.00 length: 154
 ratio: 4.848 base: 1
 Percent Similarity: 98.507 percent identity: 97.761

100. Summary: A host cell transfected or transformed with an expression system
 101. comprising the H Sdk2 nucleic acid can be used for the recombinant
 102. production of the protein. The H Sdk2 polypeptide is useful for treating
 103. a subject who requires enhanced or reduced activity or expression of inhibition
 104. of the polypeptide. Recombinant H Sdk2 is used to induce and/or inhibit
 105. receptors, to drug screens, and to identify soluble or membrane bound
 106. proteins. The H Sdk2 polypeptides are useful for treating inflammatory
 107. (rheumatoid arthritis), septicemia, autoimmune disease (inflammatory
 108. bowel disease, Crohn's disease), transplant rejection, infection, stroke,
 109. sepsis, trauma, trauma, metastasis, and other bone diseases (osteoporosis);
 110. cancer (for the inhibition of proliferation); attherosclerosis and Alzheimer's
 111. disease. The H Sdk2 nucleic acids can be used in gene therapy.

112. Sequence: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

113. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;
 114. Percent GC: 45.50 Percent GC: 45.50
 115. Percent GC: 45.50 Percent GC: 45.50
 116. Percent GC: 45.50 Percent GC: 45.50

117. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

118. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

119. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

120. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

121. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

122. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

123. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

124. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

125. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

126. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

127. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

128. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

129. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

130. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

131. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

132. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

133. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

134. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

135. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

136. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

137. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

138. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

139. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

140. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

141. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

142. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

143. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

144. Summary: 2512 bp; 782 A; 458 G; 508 G; 764 T; 0 other;

708.GAGAAAAAATAGTCTCTCAACAAAAAAT.....GAAAAAT 745

188 TTTCTGAGTAspGlyAspGlnGlySerGlyLeuGlyLeuGlySerGly 704

747 ATTATGAGTCAAGCTAATGTC.....CTCTCAAAAAATCT 761

204 STGGGAGTCTGTTTCTGTTGATGATGATGATGATGATGATGATGAT 741

762 GAAATATGATGATGATGATGATGATGATGATGATGATGATGATGAT 841

221 GATATGATGATGATGATGATGATGATGATGATGATGATGATGAT 747

832 AGCTTATGATGATGATGATGATGATGATGATGATGATGATGATGAT 872

239 TTTCTGAGTAspGlyAspGlnGlySerGlyLeuGlyLeuGlySer 744

873TTTCTGATCT 884

254 GAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 741

884 AAAAAAAG 943

271 TTTCTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 787

934 AATATGATGATGATGATGATGATGATGATGATGATGATGATGAT 943

288 TTTCTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 798

984 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 703

299AspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 708

1034 AAAAAAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1084

308 TTTCTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 724

1084 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

325 ATGATGATGATGATGATGATGATGATGATGATGATGATGAT 741

1128 AGAAAAAAG 1177

441 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 741

1178 TTTCTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

452AspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 741

1228 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

462 ATGATGATGATGATGATGATGATGATGATGATGATGATGAT 741

1275 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

478 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

1425 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

494ProGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 741

1372 ATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1415

409 GATTTGAGTAspGlnGlyLeuGlyLeuGlyLeuGlyLeuGlyLeu 727

1416 AAAAAAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1427

[illegible]

```

1238 AGAAACCAAGCAGAGGCGCCGACAGCGTGGCTGTGGTGGATGGAG 1287
510 .....|LGSFALIAIAPRPPRPTRPPTPRPPTPRPPTPRPPTA 524
1286 AACGCCTTAAGCTTGCTGGCGAGAGACTGCCCGGAGATCTAACAAAGCT 1337
525 AIAPIPLQHPPro...PReAlasorThruValIPRoAlaInlaSorSo 540
1338 GATGGCGCACGGGAGAGCGAGCATGGATTTTCAGACCAAAGAAAAGC 1387
540 rGlnAlaVaLaSnGlyMetSerArgGlyALA..... 550
1388 ACCTGACATCACCGCGCTAAAGGTGAAGCTCTTTGATTAAGGACAGGAA 1437
551 .....LeuLeuSerSerTleGIAnaSPHcInlSGLyThr 562
1438 GGCGTTGTTTTTTTGTGACATGCATAAAGATGtGTAACTTGAAG 1487
563 LeuArGlyAlaILySLyThrGys 569
....|||.....
1488 GTGCCCTGTGCTATTCTGGTGT 1508
```

SeqName: chr7:1,000,000-1,000,700_A_14412504.05_08_229-515A-14

seq_documentation_block:

Patent No. 5518885

; APPL1CAN1: KAZ101

APPLICANT: SAKKAK, FAZLOU, H

TITLE OF INVENTION: NEOPLASTIC DISEASE
NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

STREET: 127 Peachtree Street, Suite 1200

STAFF: George

COUNTRY: usa
ZIP: 30303

COMPUTER READABLE FORM

COMPUTER: IBM PC compatible

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: 115-208-2029 5154

FILING DATE: 19 APR 1994

ΑΙ ΙΟΥΝΙΑ / ΑΥΓΗΝΙ ΜΕΤΕΚΜΑΤΙΣΘΗ

NAME: PERKINMAN, DAVALL C
REGISTRATION NUMBER: 33

REFERENCE/DOCKET NUMBER: 1414.603

TELEPHONE: 404-688-0770

INFORMATION FOR SEQ ID NO: 14

SEQUENCE CHARACTERISTICS:
LENGTH: 3955 base pairs

TYPE: nucleic acid
STRANDNESS: single

TOPOLOGY:

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

alignment scores:

Quali i
pat

Percent Similari

alignment_block:

05-09-064-438-2


```

145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

```

[illegible]

[illegible]

Fri Jun 7 10:46:31 2002

us-09-684-458-2.p2n.rni

Page 18

.
.
.

[illegible][illegible]

Downloaded from <http://ajphaphysocpharm.sagepub.com/> at 11:06 11 November 2014

Downloaded from <http://ajph.org/> on November 10, 2014

Downloaded from <http://ajph.org/> on November 10, 2015

